{"id":"NCT01429077","sponsor":"Shirley Ryan AbilityLab","briefTitle":"Augmenting Language Therapy for Aphasia: Levodopa","officialTitle":"Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-10","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2011-09-05","resultsPosted":"2013-11-28","lastUpdate":"2013-12-25"},"enrollment":36,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Nonfluent Aphasia","Stroke"],"interventions":[{"type":"DRUG","name":"levodopa/carbidopa","otherNames":["Sinemet"]},{"type":"DRUG","name":"Placebo comparator","otherNames":[]}],"arms":[{"label":"Levodopa/carbidopa","type":"ACTIVE_COMPARATOR"},{"label":"Inactive pill","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effectiveness of the medication levodopa, in combination with speech-language treatment, on the language outcome of study subjects with nonfluent aphasia (i.e. difficulty with the comprehension and expression of spoken and written language) following a stroke.","primaryOutcome":{"measure":"Language Quotient (LQ) on the Western Aphasia Battery","timeFrame":"Change from Baseline in Western Aphasia Battery LQ at 6 weeks","effectByArm":[{"arm":"Levodopa/Carbidopa","deltaMin":3.16,"sd":3.63},{"arm":"Inactive Pill","deltaMin":2.59,"sd":3.41}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":[]}}